# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Surmodics (NASDAQ:SRDX) with a Buy and maintains $47 price target.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-...
Needham analyst Mike Matson maintains Surmodics (NASDAQ:SRDX) with a Buy and raises the price target from $44 to $47.
Surmodics (NASDAQ:SRDX) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.30) by ...
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NY...
The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently ...